# Discordance between gut-derived appetite hormones and

# <sup>2</sup> energy intake in humans

<sup>3</sup> Aaron Hengist<sup>1</sup>, Christina M. Sciarrillo<sup>1</sup>, Juen Guo<sup>1</sup>, Mary Walter<sup>1</sup>, Kevin D. Hall<sup>1</sup>\*

<sup>4</sup> <sup>1</sup>National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda MD, 20892,

- 5 USA
- <sup>6</sup> \*Correspondence: <u>kevin.hall@nih.gov;</u> Twitter: @KevinH\_PhD
- 7

# 8 SUMMARY

Gut-derived hormones affect appetite and are thought to play an important role in body weight 9 regulation. Dietary macronutrient composition can influence gut-derived appetite hormone 10 concentrations, thereby providing theoretical basis for why some diets might facilitate weight 11 loss better than others. We investigated postprandial gut-derived appetite hormones in 20 12 inpatient adults after 2 weeks of eating either a low carbohydrate (LC) or a low fat (LF) diet 13 followed by the alternate diet in random order. A LC meal resulted in significantly greater 14 postprandial GLP-1, GIP, and PYY but lower ghrelin compared to an isocaloric LF meal (all 15  $p \le 0.02$ ). However, differences in gut-derived appetite hormones were incommensurate with 16 subsequent ad libitum energy intake over the rest of the day, which was 551±103 kcal 17 (p<0.0001) greater with the LC as compared to the LF diet. The effects of gut-derived appetite 18 hormones on ad libitum energy intake can be dominated by other diet-related factors, at least in 19 20 the short-term.

21

## 22 Keywords

Appetite; Energy Intake; Gut Hormones; Postprandial; Low Carbohydrate; Low Fat; Diet

# 24 Graphical Abstract



## 26 INTRODUCTION

Gut-derived hormones affect appetite. Ghrelin increases hunger and decreases after food 27 intake, whereas satiation and satiety are induced by peptide YY (PYY), glucagon-like peptide-1 28 (GLP-1), and perhaps glucose-dependent insulinotropic polypeptide (GIP) which are all 29 increased after food intake.<sup>1-3</sup> These gut-derived appetite hormones have been theorized to play 30 a role in the weight-loss that results from bariatric surgery<sup>4,5</sup> and agonists of GLP-1 and GIP 31 receptors have become successful pharmacological treatments for obesity.<sup>6-8</sup> Circulating 32 concentrations of gut-derived appetite hormones can be influenced by dietary macronutrient 33 composition,<sup>9-13</sup> which provides a theoretical basis for why some diets may help facilitate weight 34 loss better than others. We recently studied 20 inpatient adults who were exposed to two diets 35 varying widely in the proportion of fat to carbohydrate for periods of 2 weeks each.<sup>14</sup> In a 36 randomized crossover design, after 2 weeks of eating a low carbohydrate (LC) diet (75% fat, 37 10% carbohydrate), the postprandial gut hormone responses to a representative LC liquid test 38 meal were compared with an isocaloric low fat (LF) liquid test meal consumed after 2 weeks of 39 eating a LF diet (10% fat, 75% carbohydrate). Subsequent ad libitum energy intake at lunch, 40 dinner, and snacks for the rest of the day were measured to investigate whether postprandial 41 responses were commensurate with subsequent intake during these dietary patterns. 42

43

## 44 **RESULTS AND DISCUSSION**

#### 45 Gut hormone responses and subsequent energy intake

At the end of each ad libitum feeding period, the LC diet resulted in greater fasting 46 concentrations of GLP-1 and GIP, but similar concentrations of PYY and leptin, and lower 47 concentrations of total ghrelin and active ghrelin, when compared to the LF diet (Table 1). 48 Figure 1 demonstrates that the LC breakfast test meal delivered at the end of the ad libitum LC 49 period resulted in greater mean postprandial plasma concentrations of active GLP-1 (LC meal: 50  $6.44\pm0.78$  pg·mL<sup>-1</sup>, LF meal: 2.46±0.26 pg·mL<sup>-1</sup>; p<0.0001), total GIP (LC meal: 578±60 pg·mL<sup>-1</sup>, 51 LF meal: 319±37 pg·mL<sup>-1</sup>; p=0.0002), and PYY (LC meal: 65.6±5.6 pg·mL<sup>-1</sup>, LF meal: 50.7±3.8 52 pg·mL<sup>-1</sup>; p=0.02) whereas total ghrelin (LC meal: 184±25 pg·mL<sup>-1</sup>, LF meal: 261±47 pg·mL<sup>-1</sup>; 53 p=0.0009), active ghrelin (LC meal: 91±9 pg mL<sup>-1</sup>, LF meal: 232±28 pg mL<sup>-1</sup>; p<0.0001), and 54 leptin (LC meal: 26.9±6.5 ng·mL<sup>-1</sup>, LF meal: 35.2±7.5 ng·mL<sup>-1</sup>; p=0.01) were lower as compared 55 to an isocaloric LF breakfast test meal delivered at the end of the ad libitum LF period. 56

#### 57

After the breakfast test meal, ad libitum energy intake was greater during the LC diet at lunch 58  $(244\pm85 \text{ kcal}; p=0.001)$  and dinner  $(193\pm86 \text{ kcal}; p=0.04)$ , but not snacks  $(114\pm63 \text{ kcal}; p=0.12)$ . 59 such that the total ad libitum energy intake over the rest of the day was significantly greater 60 (551±103 kcal; p<0.0001) as compared to when the same participants consumed the LF diet 61 (Figure 2A). Within each diet pattern, there were no significant correlations between 62 subsequent ad libitum energy intake and the mean postprandial active GLP-1 (LC diet; r=-0.1; 63 p=0.68, LF diet: r=-0.12; p=0.60), total GIP (LC diet: r=-0.08; p=0.73, LF diet: r=0.23; p=0.34), 64 PYY (LC diet: r=-0.23; p=0.32, LF diet: r=-0.007; p=0.98), total ghrelin (LC diet: r=0.31; p=0.19, 65 LF diet: r=0.32; p=0.16), active ghrelin (LC diet: r=0.20; p=0.41, LF diet: r=0.07; p=0.76), or 66 leptin (LC diet: r=-0.07; p=0.77, LF diet: r=-0.26; p=0.27). 67

68

The present cohort had a wide range of body mass indices, therefore diet by BMI interactions were explored to investigate if any of the differences in gut hormone responses were driven by BMI (**Figure S1**). The only significant diet by BMI interaction was observed for active ghrelin, which was greater in LF than LC in individuals with a BMI below 25 kg.m<sup>-2</sup> (p<0.0001), but was not significiantly different in individuals with overweight (p=0.48) or obesity (p=0.25).

74

The observed differences in gut-derived appetite hormones during the LC test meal would be expected to result in reduced appetite and lower ad libitum energy intake as compared to the LF diet. However, the opposite result was observed, with the LC diet resulting in an additional ~500 kcal consumed over the remainder of the day following the test meal, as compared to the LF diet. This difference was similar to the overall ~700 kcal·d<sup>-1</sup> difference between the diets averaged over two weeks.<sup>14</sup>

81

Concentrations of the adipokine leptin were commensurate with the direction of ad libitum energy intake differences for the LC and LF diets. The lower leptin following the LC diet (*vs* LF) is in agreement with previous evidence comparing a ketogenic low carbohydrate diet with an isocaloric diet moderate in both carbohydrate and fat.<sup>15</sup> The decrease in leptin following LC is likely explained by decreased insulin and glucose concentrations, which were lower in LC compared to LF.<sup>14</sup> Previous studies have shown that small increases in insulin induced by

alucose infusion of 2.5 mg·kg<sup>-1</sup>·min were sufficient to offset the decrease in leptin observed with 88 16 hours of fasting<sup>16</sup> and 24 hours of ketogenic carbohydrate restriction reduced leptin 89 concentrations independent from changes in ad libitum energy intake and preceding changes in 90 adiposity.<sup>17</sup> Therefore, the evidence suggests that changes in carbohydrate availability, rather 91 than energy intake or energy balance, are key for altering leptin concentrations. Decreased 92 leptin would theoretically increase appetite, as has been associated following weight loss.<sup>18</sup> 93 Whilst it is possible that leptin, as a longer-term appetite signal, overrides the transient signals 94 from gut-derived hormones, leptin concentrations did not correlate with ad libitum energy intake 95 in the present study, so it is likely that other diet-related factors are more important in this 96 context. 97

98

#### <sup>99</sup> Influence of macronutrient composition on gut hormone response

Although the LC and LF diets differed by more than just their macronutrient composition, it is 100 likely that the differences in gut hormone responses were mainly due to macronutrient 101 differences as previously reviewed.<sup>19,20</sup> Early evidence in humans suggested that small 102 increases in GLP-1 were observed after isocaloric carbohydrate (glucose), fat (double cream), 103 or protein (lean turkey) ingestion, whereas GIP only responded to carbohydrate and fat.<sup>21</sup> 104 However, regardless of nutrient, the food matrix also plays a large role in determining 105 postprandial responses as demonstrated by isocaloric ingestion of glucose eliciting greater 106 GLP-1 and GIP responses than whole food sources of carbohydrate, including brown rice or 107 pearl barley.<sup>21</sup> With regards to carbohydrate manipulation, the increase in PYY observed 108 following LC in the present study resembles the results of a similar randomized crossover study 109 in participants with obesity who consumed isocaloric low-carbohydrate or low-fat diets for one 110 week before ingesting a representative breakfast meal.<sup>22</sup> Similarly, high-fat drinks (38% 111 carbohydrate, 50% fat) increase postprandial GLP-1 and PYY responses, without differences in 112 postprandial ghrelin responses, compared to isocaloric (590 kcal) low-fat, high-carbohydrate 113 drinks (84% carbohydrate, 3% fat), but these differences did not translate into differences in ad 114 libitum energy intake in a subsequent lunch meal.<sup>10</sup> Instead, ad libitum intake was associated 115 with ahrelin responses, which contrasts with our results because total and active ghrelin were 116 reduced with the LC diet in comparison to the LF diet and did not correlate with energy intake. 117

Macronutrient manipulation, with food volume and energy density controlled, has been shown to 119 alter postprandial GLP-1, GIP, PYY, active ghrelin, and total ghrelin responses, but did not alter 120 subjective hunger or subsequent energy intake.<sup>9,12,13</sup> Over the course of our study, the LF diet 121 resulted in ~700 kcal d<sup>-1</sup> less ad libitum energy intake as compared to the LC diet without 122 significant differences in self-reported appetite.<sup>14</sup> Because postprandial responses of gut-123 derived appetite hormones depend on the amount of food consumed,<sup>23,24</sup> the expected diet 124 differences in postprandial ghrelin, GLP-1, GIP, and PYY during the ad libitum period would 125 likely be even greater than we observed following the isocaloric meal tests and further 126 emphasizes that the expected effects of these appetite hormone differences were dominated by 127 other diet differences. 128

129

#### 130 Diet-related factors affecting energy intake beyond gut hormones

Recent analysis of the meal characteristics that affect energy intake from our inpatient feeding 131 studies suggests that energy density, eating rate, and proportion of hyper-palatable foods are 132 positively associated with meal energy intake.<sup>25</sup> Greater dietary energy density has consistently 133 been shown to increase energy intake in short-term interventions.<sup>26</sup> The LC diet of the present 134 study had about double the energy density of the LF diet and mediated around 25% of the diet 135 effect on meal energy intake.<sup>25</sup> A guicker eating rate increases energy intake of presented 136 meals without altering subsequent hunger.<sup>27</sup> Eating rate could be related to sensory and 137 physical properties of foods, like food texture;<sup>28</sup> for example, softer, less solid, less viscous 138 foods are associated with increased eating rate.<sup>29</sup> Eating rate in grams per minute was guicker 139 in the LF meals at lunch (29±9 g min<sup>-1</sup>, p<0.0001) and dinner (14±9 g min<sup>-1</sup>, p=0.009) on the test 140 meal day, compared to LC, so this factor is unlikely to explain our observations of increased 141 energy intake on the LC test meal day. The volume and mass of food ingested is closely related 142 to energy density, which may alter gastric distension and contribute to changes in gut hormone 143 responses to meals.<sup>30</sup> The mass of food eaten ad libitum was significantly greater following the 144 LF diet at lunch and dinner, but not snacks (Figure 2B), compared to LC. This total difference 145 across the day was consistent with the overall ~667 g·d<sup>-1</sup> difference between the diets averaged 146 over two weeks.<sup>14</sup> Within each diet pattern, there were no significant correlations between 147 postprandial gut hormone responses following the liquid test meals and subsequent mass of 148 food eaten at lunch (first subsequent meal) or throughout the day of the test meal (Table S1), 149 apart from a moderate negative correlation between food mass intake at lunch in the LF diet 150 and leptin. Hyper-palatable foods have recently been defined using quantitative thresholds of 151

nutrient combinations that may drive excess intake; 1) fat and sugar (>20% energy, >20% 152 energy), 2) fat and sodium (>20% of energy, >0.3% by weight), and 3) carbohydrates and 153 sodium (>40% energy, >0.3% by weight).<sup>31</sup> Across the entire 2 weeks, meals in the LC diet had 154 a greater proportion of hyper-palatable foods than the LF diet, which may have mediated around 155 14% of the diet effect on meal energy intake.<sup>25</sup> The availability of hyperpalatable foods in the US 156 food system, by this definition, has increased from around 49% to around 69% in 30 years.<sup>32</sup> 157 Emerging cross-sectional evidence suggests that hyper-palatable foods may be more 158 rewarding.<sup>33</sup> More work is required to determine the utility of quantitative definitions of hyper-159 palatability and their influence on food intake. Whilst the alternative diet-related factors 160 discussed may often be inter-related in real world settings, it is important for future work to 161 isolate these diet-related factors and test their contribution to ad libitum energy intake in 162 different dietary contexts (e.g. macronutrient manipulation or processing). 163

164

#### 165 **Comparisons between diet and pharmacological or surgical interventions**

Discordance between gut hormone responses and energy intake in the present study may 166 appear to contradict the recent success of pharmacological gut hormone mimetics, including 167 GLP-1 receptor agonists, but quantitative considerations of dose and exposure reconcile our 168 findings. Specifically, the estimated active GLP-1 steady state average exposure concentration, 169  $C_{\text{avg}},$  for the present study had mean (95% CI) values of 0.034 (0.029, 0.043) nmol·L^1 for LF 170 and 0.086 (0.071, 0.113) nmol·L<sup>-1</sup> for LC, which are orders of magnitude lower than the Cava of 171 both oral and subcutaneous semaglutide ranging from  $\sim 3$  nmol·L<sup>-1</sup> up to  $\sim 30$  nmol·L<sup>-1</sup> with oral 172 and subcutaneous semaglutide, respectively (Figure 3A).<sup>34</sup> Such high Cava with 173 pharmacological treatment is due to the long half-life of semaglutide which has a similar binding 174 affinity to the GLP-1 receptor as native GLP-1,<sup>35</sup> whereas the half-life of endogenous GLP-1 and 175 GIP is minutes in humans.<sup>36</sup> Unlike pharmacological intervention, diet-induced changes in gut 176 hormone concentrations reflect conjoint changes of multiple hormones in a complex signalling 177 system, so the quantitative exposure of GLP-1 from diet and pharmacological interventions 178 cannot be compared directly, but this comparison highlights that the magnitude of change in 179 GLP-1 from diet is not comparable to that of pharmacological interventions even with the 180 concurrent changes of other hormones. 181

Pharmacological engagement of the GLP-1 receptor (e.g. exogenous GLP-1) may act differently 183 from nutrient-stimulated gut hormones (e.g. endogenous GLP-1). For example, endogenous 184 GLP-1 may affect the hypothalamus through neuronal signaling from the gut to brain via solitary 185 tract neurons, whereas exogenous GLP-1 receptor agonists may directly engage hypothalamic 186 and brainstem GLP-1 receptors.<sup>6</sup> Further complicating this, GLP-1 can be produced centrally in 187 brain regions which may directly alter appetite independent from diet-induced gut hormone 188 secretion.<sup>37</sup> With this context, changes in endogenous gut hormone concentrations induced by 189 diet may be not be potent enough to affect energy intake. Indeed, mouse models that knockout 190 the GLP-1 receptor,<sup>38</sup> or delete intestinal GLP-1 production throught GNG gene knockout,<sup>39</sup> do 191 not result in a body weight or food intake phenotype, suggesting that endogenous GLP-1 has a 192 limited effect on appetite in the normal physiological range. 193

194

Some forms of bariatric surgery result in substantial increases in postprandial GLP-1 and 195 PYY,<sup>40-42</sup> likely due to altered gastric emptying and intestinal nutrient delivery. The magnitude of 196 post-surgical changes in postprandial gut hormone responses might be mechanistically linked to 197 reduced appetite and energy intake. Infusion of GLP-1, PYY, and oxyntomodulin in healthy 198 participants that mimics the concentrations observed following Roux-en-Y gastric bypass 199 reduced energy intake at lunch and dinner by ~400 kcal.<sup>3</sup> The active GLP-1 and PYY 200 concentrations achieved were around 26 pmol·L<sup>-1</sup> (85 pg·mL<sup>-1</sup>) and 80 pmol·L<sup>-1</sup> (320 pg·mL<sup>-1</sup>) 201 respectively. For active GLP-1, these concentrations are around 13-fold and 35-fold greater 202 than mean postprandial concentrations following the LC and LF meals in the present study, and 203 for PYY they are around 5-fold and 6-fold greater (Figure 3B). Infusing GLP-1 to achieve 204 concentrations comparable with the LC condition of the present study (~15 pg·mL<sup>-1</sup>) delays 205 gastric emptying without suppressing subjective appetite and ad libitum intake.<sup>43</sup> 206 Supraphysiological concentrations of GLP-1 achieved by infusion (~25 to 30 pg mL<sup>-1</sup>) suppress 207 subjective appetite, but effects on subsequent ad libitum energy intake are modest compared 208 with higher concentrations (~100 to 240 kcal).<sup>44,45</sup> Together, infusion studies indicate a dose-209 response relationship between active GLP-1 and suppression of appetite,<sup>46</sup> and suggest that 210 substantially greater increases in gut hormone concentrations are required to have meaningful 211 effects on appetite and energy intake, likely greater than is achievable by diet interventions 212 alone. 213

#### 215 Limitations and considerations

A limitation of the current study is that participants had no choice regarding the foods available 216 for consumption. They could only choose the quantity of the foods eaten. While the gut-derived 217 appetite hormones were not a dominant factor determining energy intake in this setting, it is 218 possible that such differences in appetite hormones in a real-world setting might alter food 219 choices at subsequent meals and thereby alter energy intake. Another limitation is that we used 220 isocaloric liquid test meals that matched the macronutrient composition of the overall LC and LF 221 diets. These test meals may have not been adequately representative of the effects of meals 222 with solid foods. Furthermore, the results reported in this study were from analyses that were 223 not pre-specified as primary or secondary outcomes of the main study and are hence 224 exploratory in nature. Nevertheless, our study suggests that differences in dietary factors like 225 energy density or proportion of hyper-palatable foods may play a greater role in appetite 226 regulation than endogenous gut-derived appetite hormones, at least in the short term. Future 227 research should aim to identify such diet differences that influence energy intake and evaluate 228 whether their effects and their potential discordance with gut-dervied appetite hormones persist 229 over time. 230

### 231 **ACKNOWLEDGEMENTS**

This work was supported by the Intramural Research Program of the NIH, National Institute of Diabetes & Digestive & Kidney Diseases under award number 1ZIADK013037. We thank the nursing and nutrition staff at the NIH Metabolic Clinical Research Unit for their invaluable assistance with this study. We thank the study participants for their invaluable contribution.

## 236 AUTHOR CONTRIBUTIONS

KDH designed the study, MW performed the biochemical analyses, JG and KDH analyzed the
 data, AH, CMS, JG, and KDH interpreted the data, drafted the manuscript, and approved the
 final version.

#### 240 **DECLARATION OF INTERESTS**

The authors declare no competing interests.

## 242 Figures

Figure 1. Postprandial responses to isocaloric low carbohydrate (LC) or low fat (LF) meals following habituation to each diet in a randomized crossover design. Mean (range) of energy in the test meals was 777 (532 to 1043) kcal. Data are mean  $\pm$  SEM. n=20. *p*-values from paired t-test of mean postprandial plasma concentrations.

- 247 (A) active glucagon-like peptide-1 (GLP-1)
- 248 (B) total glucose-dependent insulinotropic polypeptide (GIP)
- 249 (C) peptide YY (PYY)
- 250 (D) leptin
- 251 (E) total ghrelin
- 252 (F) active ghrelin



Figure 2. Total intake, and intake from lunch, dinner, and snacks throughout the day after isocaloric low carbohydrate (LC) or low fat (LF) meals following habituation to each diet in a randomized crossover design. Mean (range) of energy in the test meals was 777 (532 to 1043) kcal. Data are mean ± SEM and individual responses. n=20. *p*-values from paired t-test or Wilcoxon test. (A) Energy intake (EI) (kcal)





Figure 3. Comparisons between dietary macronutrient induced changes in gut hormone responses and pharmacological or bariatric surgery induced changes.

(A) estimated mean active GLP-1 steady state average exposure concentrations, C<sub>avg</sub>, achieved by
 low carbohydrate (LC) or low fat (LF) diet were orders of magnitude lower than the both oral and
 subcutaneous semaglutide using values median (90% exposure ranges) from Overgaard et al.<sup>34</sup>

(B) peak active GLP-1 and PYY concentrations following a LC or LF test meal were orders of magnitude lower than peak concentrations observed during a mixed-meal test following Roux-en-

Y Gastric Bypass surgery (RYGB) using data from Tan et al.<sup>3</sup> Data are mean  $\pm$  SEM.



# 270 Tables

Table 1. Fasting concentrations of gut-derived appetite hormones and leptin in the second week of low carbohydrate (LC) or low fat (LF) diet. Data are mean  $\pm$  SEM, n=20.

273

	LC LF		p value LC <i>v</i> s LF
Active GLP-1 (pg⋅mL <sup>-1</sup> )	$0.96 \pm 0.14$	$0.61\pm0.06$	0.01
Total GIP (pg⋅mL⁻¹)	$80\pm13$	$56\pm 8$	0.03
PYY (pg⋅mL <sup>-1</sup> )	$38.2 \pm 3.2$	$38.0\pm3.7$	0.94
Total ghrelin (pg⋅mL⁻¹)	$263\pm48$	$329\pm55$	0.004
Active ghrelin (pg⋅mL <sup>-1</sup> )	$116\pm21$	$238\pm30$	0.0002
Leptin (ng⋅mL <sup>-1</sup> )	$28.2 \pm 6.7$	$33.5\pm7.8$	0.39

## 275 STAR Methods

## 276 KEY REOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Biological samples		
Human serum and plasma	NCT03878108	https://www.clinicaltrials.gov/study/NCT
·		03878108
Critical commercial assays		
U-plex multiplex assay	Meso Scale Diagnostics	K15281K
Deposited data		
Raw human data	This paper	https://osf.io/fjykq/

277

#### 278 **RESOURCE AVAILABILITY**

#### 279 Lead contact

Further information and requests for resources and reagents should be directed to and will be

<sup>281</sup> fulfilled by the Lead Contact Dr Kevin Hall (<u>kevin.hall@nih.gov</u>).

#### 282 Materials availability

<sup>283</sup> This study did not generate new unique reagents.

#### 284 Data and code availability

- De-identified data have been deposited at <u>https://osf.io/fjykq/</u> and are publicly available as of the
- date of publication. This paper does not report original code.

287

#### 288 EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS

These data are exploratory endpoints from a registered clinical trial conducted at the Metabolic 289 Clinical Research Unit at the NIH Clinical Center and approved by the institutional board of the 290 National Institute of Diabetes & Digestive & Kidney Diseases (NCT03878108). Detailed 291 methods have been published previously.<sup>14</sup> Participants completed a single four week stay and 292 completed 2 diets in a randomized order. One diet was an animal-based, ketogenic, low 293 carbohydrate (LC) diet with ~10% of energy from carbohydrates, ~75% from fat and the other 294 diet was a plant-based, low fat (LF) diet with ~10% of energy from fat, ~75% from carbohydrate. 295 Inclusion criteria were male and female adults age 18-50 years; weight stable (within 5% in past 296

6 months); body mass index  $\geq 20 \square \text{kg} \cdot \text{m}^{-2}$ ; body weight  $\geq 53 \square \text{kg}$ ; able to complete daily bouts of 297 stationary cycling at a moderate rate and intensity with a heart rate (HR) equal to or greater than 298 0.3 × (220 – age – HRrest) + HRrest but exceeding not 299 0.4 × (220 – age – HRrest) + HRrest and no signs of arrhythmia. Exclusion criteria 300 were evidence of metabolic or cardiovascular disease or disease that may influence metabolism 301 (for example cancer, diabetes, thyroid disease); taking any prescription medication or other drug 302 that may influence metabolism (for example diet/weight-loss medication, asthma medication, 303 blood pressure medication, psychiatric medications, corticosteroids or other medications at the 304 discretion of the study team); positive pregnancy test or lactation as determined by volunteer 305 report (women only); participating in a regular exercise program (>2 $\Box$ h $\Box$ week-1 of vigorous 306 activity); hematocrit <37% for women and <40% for men; habitual caffeine consumption 307  $>300 \square mg \square d-1$ ; regular use of alcohol (>2 drinks per day), tobacco (smoking or chewing), 308 amphetamines, cocaine, heroin or marijuana over past 6 months; psychological conditions such 309 as (but not limited to) eating disorders, claustrophobia, clinical depression, bipolar disorders, as 310 determined by investigators after reviewing the results of the DSM-5 Self-Rated Level 1 Cross-311 Cutting Symptom Measure: past or present history of claustrophobia: implants, devices or 312 foreign objects implanted in the body that interfere with the magnetic resonance procedures; 313 strict dietary concerns (for example vegetarian or kosher diet, food allergies) as determined by 314 investigators after reviewing the results of the Food Frequency Questionnaire; volunteers 315 unwilling or unable to give informed consent; and non-English speakers owing to unavailability 316 of required questionnaires in other languages. Participants were 20 adults (male n=11, female 317 n=9; mean $\pm$ SD, age 30 $\pm$ 6 years; body mass 80.8 $\pm$ 18.2 kg; body mass index 27.8 $\pm$ 5.9 kg m<sup>-2</sup>; fat 318 mass 26.9±11.2 kg; body fat percentage 32.8±9.8%; resting energy expenditure 1550±287 319 kcal·d<sup>-1</sup>). 320

321

#### 322 METHOD DETAILS

At the end of the second inpatient week of consuming either the ad libitum low carbohydrate (LC) or low fat (LF) diets and after an overnight fast, participants consumed liquid meals matching the macronutrient content of the prevailing diet and amounting to 30% of the estimated daily calorie requirements as determined by 1.6 multiplied by the resting energy expenditure measured at screening. Mean (range) of energy in the test meals was 777 (532 to 1043) kcal. The LC test meal was 10% carbohydrate, 75% fat, and 15% protein whereas the LF

test meal was 75% carbohydrate, 10% fat, and 15% protein. Blood samples were obtained at 0,
10, 20, 30, 60, 90, 120, 180, 240, 300, and 360 minutes after the meals in tubes containing a
protease inhibitor cocktail (including DPPIV inhibitor and aprotinin) to measure GLP-1, GIP,
PYY, total ghrelin, active ghrelin, and leptin using multiplex immunoassays (Meso Scale
Diagnostics).

334

After the breakfast mixed meal tests, ad libitum food intake was measured over the rest of the 335 day including lunch, dinner, and snacks by weighing the remaining food and beverages to 336 calculate the amount of each food consumed and energy intake was calculated using ProNutra 337 software (v.3.4. Viocare) with nutrient values derived from the USDA National Nutrient Database 338 339 for Standard Reference, Release 26 and the USDA Food and Nutrient Database for Dietary 340 Studies, 4.0. Statistical analyses were performed using SAS (v.9.4; SAS Institute) and Prism (v.9.5.0; GraphPad). Mean plasma concentrations were calculated by dividing total area under 341 the curve (tAUC) by 360 minutes. Active GLP-1 Cava was estimated by multiplying the 6-hour 342 postprandial tAUC by 3 (18 h) and multiplying the postabsorptive (fasting) concentration by 360 343 minutes (6 h), to get 24-hour exposure, and dividing by 24. The conversion factor used for GLP-344 1 was 1 pmol  $L^{-1} = 3.297$  pg mL<sup>-1</sup>. Data were checked for normality using Shapiro-Wilk test, 345 differences between conditions were assessed using paired t-tests for normally distributed and 346 Wilcoxon tests for non-normally distributed data. Simple linear correlation was used to explore 347 associations between gut hormone responses and ad libitum energy intake. Diet by BMI 348 interactions were checked using 2-way ANOVA, with post-hoc Bonferroni tests used to identify 349 differences. Significance was accepted as  $p \le 0.05$ . 350

## 351 SUPPLEMENTAL INFORMATION

352

- <sup>353</sup> Discordance between gut-derived appetite hormones and energy intake in humans
- Aaron Hengist, Christina M. Sciarrillo, Juen Guo, Mary Walter, Kevin D. Hall

355

356 This document contains 1 supplemental figure and 1 supplemental table.

- $_{357}$  Figure S1. Gut hormone responses sub-divided into body mass index categories. Data are mean  $\pm$
- 358 SEM and individual responses. n=20. *p*-values from two-way ANOVA of diet by BMI category.
- 359 (A) Participants split by BMI category
- 360 (B) Total energy intake
- 361 (C) active glucagon-like peptide-1 (GLP-1)
- 362 (D) total glucose-dependent insulinotropic polypeptide (GIP)
- 363 (E) peptide YY (PYY)
- 364 (F) leptin
- 365 (G) total ghrelin
- 366 (H) active ghrelin



Table S1. Correlations between mean postprandial responses to isocaloric low carbohydrate (LC) or low fat (LF) meals following habituation to each diet in a randomized crossover design with the

subsequent mass intake in the lunch meal and total intake across the day following the test meal.

371

	Subsequent lunch		Subsequent total mass	
	mass intake during test		intake during test meal	
	meal day		day	
Mean postprandial concentrations	LC	LF	LC	LF
Active GLP-1	-0.11	-0.21	-0.12	-0.14
	(0.63)	(0.37)	(0.62)	(0.55)
Total GIP	-0.20	-0.06	-0.15	0.22
	(0.39)	(0.79)	(0.54)	(0.36)
ΡΥΥ	-0.22	0.07	-0.33	0.10
	(0.36)	(0.76)	(0.15)	(0.68)
Total ghrelin	-0.30	0.44	-0.06	0.38
	(0.20)	(0.0504)	(0.82)	(0.10)
Active ghrelin	0.004	0.35	0.06	0.20
	(0.99)	(0.13)	(0.81)	(0.39)
Leptin	-0.06	-0.48	-0.07	-0.40
	(0.81)	(0.03)	(0.76)	(0.08)

<sup>372</sup> Data are Pearson's r (p-value). n=20.

## 373 **REFERENCES**

- 1. Samms, R.J., Goghlan, M.P., and Sloop, K.W. (2020). How May GIP Enhance the Therapeutic Efficacy of GLP-1? Trends in Endocrinology and Metabolism *31*, 410-421. 10.1016/j.tem.2020.02.006.
- 2. Sato, T., Nakamura, Y., Shiimura, Y., Ohgusu, H., Kangawa, K., and Kojima, M. (2012). Structure, regulation and function of ghrelin. J Biochem *151*, 119-128. 10.1093/jb/mvr134.
- 378 3. Tan, T., Behary, P., Tharakan, G., Minnion, J., Al-Najim, W., Albrechtsen, N.J.W., Holst, J.J., and Bloom,
   S.R. (2017). The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and
   Expenditure in Obese Volunteers. The Journal of clinical endocrinology and metabolism *102*,
   2364-2372. 10.1210/jc.2017-00469.
- 4. Holst, J.J., Madsbad, S., Bojsen-Moller, K.N., Svane, M.S., Jorgensen, N.B., Dirksen, C., and Martinussen, C. (2018). Mechanisms in bariatric surgery: Gut hormones, diabetes resolution, and weight loss. Surg Obes Relat Dis *14*, 708-714. 10.1016/j.soard.2018.03.003.
- 5. Troke, R.C., Tan, T.M., and Bloom, S.R. (2014). The future role of gut hormones in the treatment of obesity. Ther Adv Chronic Dis *5*, 4-14. 10.1177/2040622313506730.
- 6. Drucker, D.J., and Holst, J.J. (2023). The expanding incretin universe: from basic biology to clinical translation. Diabetologia. 10.1007/s00125-023-05906-7.
- 7. Jastreboff, A.M., Aronne, L.J., Ahmad, N.N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S.,
   Liu, B., Bunck, M.C., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J
   Med 387, 205-216. 10.1056/NEJMoa2206038.
- Wilding, J.P.H., Batterham, R.L., Calanna, S., Davies, M., Van Gaal, L.F., Lingvay, I., McGowan, B.M.,
   Rosenstock, J., Tran, M.T.D., Wadden, T.A., et al. (2021). Once-Weekly Semaglutide in Adults
   with Overweight or Obesity. N Engl J Med *384*, 989-1002. 10.1056/NEJMoa2032183.
- 9. Foster-Schubert, K.E., Overduin, J., Prudom, C.E., Liu, J., Callahan, H.S., Gaylinn, B.D., Thorner, M.O.,
   and Cummings, D.E. (2008). Acyl and total ghrelin are suppressed strongly by ingested proteins,
   weakly by lipids, and biphasically by carbohydrates. The Journal of clinical endocrinology and
   metabolism *93*, 1971-1979. 10.1210/jc.2007-2289.
- 10. Gibbons, C., Caudwell, P., Finlayson, G., Webb, D.L., Hellstrom, P.M., Naslund, E., and Blundell, J.E.
   (2013). Comparison of postprandial profiles of ghrelin, active GLP-1, and total PYY to meals
   varying in fat and carbohydrate and their association with hunger and the phases of satiety. The
   Journal of clinical endocrinology and metabolism *98*, E847-855. 10.1210/jc.2012-3835.
- 11. Helou, N., Obeid, O., Azar, S.T., and Hwalla, N. (2008). Variation of postprandial PYY 3-36 response
  following ingestion of differing macronutrient meals in obese females. Ann Nutr Metab *52*, 188195. 10.1159/000138122.
- Raben, A., Agerholm-Larsen, L., Flint, A., Holst, J.J., and Astrup, A. (2003). Meals with similar energy
   densities but rich in protein, fat, carbohydrate, or alcohol have different effects on energy
   expenditure and substrate metabolism but not on appetite and energy intake. Am J Clin Nutr 77,
   91-100. DOI 10.1093/ajcn/77.1.91.
- 13. van der Klaauw, A.A., Keogh, J.M., Henning, E., Trowse, V.M., Dhillo, W.S., Ghatei, M.A., and Farooqi,
  I.S. (2013). High Protein Intake Stimulates Postprandial GLP1 and PYY Release. Obesity *21*, 16021607. 10.1002/oby.20154.
- 14. Hall, K.D., Guo, J., Courville, A.B., Boring, J., Brychta, R., Chen, K.Y., Darcey, V., Forde, C.G., Gharib,
   A.M., Gallagher, I., et al. (2021). Effect of a plant-based, low-fat diet versus an animal-based,
   ketogenic diet on ad libitum energy intake. Nat Med 27, 344-353. 10.1038/s41591-020-01209-1.
- Hall, K.D., Chen, K.Y., Guo, J., Lam, Y.Y., Leibel, R.L., Mayer, L.E., Reitman, M.L., Rosenbaum, M.,
  Smith, S.R., Walsh, B.T., and Ravussin, E. (2016). Energy expenditure and body composition
  changes after an isocaloric ketogenic diet in overweight and obese men. Am J Clin Nutr *104*,
  324-333. 10.3945/ajcn.116.133561.

- Sonnenberg, G.E., Krakower, G.R., Hoffmann, R.G., Maas, D.L., Hennes, M.M., and Kissebah, A.H.
   (2001). Plasma leptin concentrations during extended fasting and graded glucose infusions:
   relationships with changes in glucose, insulin, and FFA. The Journal of clinical endocrinology and
   metabolism *86*, 4895-4900. 10.1210/jcem.86.10.7951.
- Hengist, A., Davies, R.G., Rogers, P.J., Brunstrom, J.M., van Loon, L.J.C., Walhin, J.P., Thompson, D.,
  Koumanov, F., Betts, J.A., and Gonzalez, J.T. (2022). Restricting sugar or carbohydrate intake
  does not impact physical activity level or energy intake over 24 h despite changes in substrate
  use: a randomised crossover study in healthy men and women. Eur J Nutr. 10.1007/s00394-02203048-x.
- 18. Keim, N.L., Stern, J.S., and Havel, P.J. (1998). Relation between circulating leptin concentrations and
   appetite during a prolonged, moderate energy deficit in women. Am J Clin Nutr *68*, 794-801.
   10.1093/ajcn/68.4.794.
- 432 19. Bodnaruc, A.M., Prud'homme, D., Blanchet, R., and Giroux, I. (2016). Nutritional modulation of
  433 endogenous glucagon-like peptide-1 secretion: a review. Nutr Metab (Lond) 13, 92.
  434 10.1186/s12986-016-0153-3.
- 435 20. Watkins, J.D., Koumanov, F., and Gonzalez, J.T. (2021). Protein- and Calcium-Mediated GLP-1 436 Secretion: A Narrative Review. Adv Nutr *12*, 2540-2552. 10.1093/advances/nmab078.
- 21. Elliott, R.M., Morgan, L.M., Tredger, J.A., Deacon, S., Wright, J., and Marks, V. (1993). Glucagon-like
   peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response
   to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol *138*,
   159-166. 10.1677/joe.0.1380159.
- 22. Essah, P.A., Levy, J.R., Sistrun, S.N., Kelly, S.M., and Nestler, J.E. (2007). Effect of macronutrient
  composition on postprandial peptide YY levels. Journal of Clinical Endocrinology & Metabolism *92*, 4052-4055. 10.1210/jc.2006-2273.
- 444 23. Hengist, A., Edinburgh, R.M., Davies, R.G., Walhin, J.P., Buniam, J., James, L.J., Rogers, P.J., Gonzalez,
  445 J.T., and Betts, J.A. (2020). Physiological responses to maximal eating in men. The British journal
  446 of nutrition *124*, 407-417. 10.1017/S0007114520001270.
- 24. Lewis, H.B., Ahern, A.L., Solis-Trapala, I., Walker, C.G., Reimann, F., Gribble, F.M., and Jebb, S.A.
  (2015). Effect of reducing portion size at a compulsory meal on later energy intake, gut
  hormones, and appetite in overweight adults. Obesity (Silver Spring) 23, 1362-1370.
  10.1002/oby.21105.
- 451 25. Fazzino, T.L., Courville, A.B., Guo, J., and Hall, K.D. (2023). Ad libitum meal energy intake is positively
   452 influenced by energy density, eating rate and hyper-palatable food across four dietary patterns.
   453 Nat Food. 10.1038/s43016-022-00688-4.
- 26. Robinson, E., Khuttan, M., McFarland-Lesser, I., Patel, Z., and Jones, A. (2022). Calorie reformulation:
   a systematic review and meta-analysis examining the effect of manipulating food energy density
   on daily energy intake. Int J Behav Nutr Phy *19*. ARTN 48
- 457 10.1186/s12966-022-01287-z.
- 27. Robinson, E., Almiron-Roig, E., Rutters, F., de Graaf, C., Forde, C.G., Smith, C.T., Nolan, S.J., and Jebb,
   S.A. (2014). A systematic review and meta-analysis examining the effect of eating rate on energy
   intake and hunger. Am J Clin Nutr *100*, 123-151. 10.3945/ajcn.113.081745.
- 28. Forde, C.G., and de Graaf, K. (2022). Influence of Sensory Properties in Moderating Eating Behaviors
   and Food Intake. Frontiers in Nutrition *9*. ARTN 841444

463 10.3389/fnut.2022.841444.

29. Appleton, K.M., Newbury, A., Almiron-Roig, E., Yeomans, M.R., Brunstrom, J.M., de Graaf, K., Geurts, L., Kildegaard, H., and Vinoy, S. (2021). Sensory and physical characteristics of foods that impact

food intake without affecting acceptability: Systematic review and meta-analyses. Obesity
 Reviews 22. 10.1111/obr.13234.

- 468 30. Cummings, D.E., and Overduin, J. (2007). Gastrointestinal regulation of food intake. The Journal of 469 clinical investigation *117*, 13-23. 10.1172/JCl30227.
- 470 31. Fazzino, T.L., Rohde, K., and Sullivan, D.K. (2019). Hyper-Palatable Foods: Development of a
  471 Quantitative Definition and Application to the US Food System Database. Obesity 27, 1761472 1768. 10.1002/oby.22639.
- 32. Demeke, S., Rohde, K., Chollet-Hinton, L., Sutton, C., Kong, K.L., and Fazzino, T.L. (2023). Change in
  hyper-palatable food availability in the US food system over 30 years: 1988-2018. Public health
  nutrition 26, 182-189. Pii S1368980022001227
- 476 10.1017/S1368980022001227.
- 477 33. Fazzino, T.L., Bjorlie, K., Rohde, K., Smith, A., and Yi, R. (2022). Choices Between Money and Hyper478 Palatable Food: Choice Impulsivity and Eating Behavior. Health Psychol *41*, 538-548.
  479 10.1037/hea0001185.
- 34. Overgaard, R.V., Hertz, C.L., Ingwersen, S.H., Navarria, A., and Drucker, D.J. (2021). Levels of
   circulating semaglutide determine reductions in HbA1c and body weight in people with type 2
   diabetes. Cell Rep Med 2, 100387. 10.1016/j.xcrm.2021.100387.
- 483 35. Overgaard, R.V., Navarria, A., Ingwersen, S.H., Baekdal, T.A., and Kildemoes, R.J. (2021). Clinical
   484 Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials. Clin
   485 Pharmacokinet 60, 1335-1348. 10.1007/s40262-021-01025-x.
- Meier, J.J., Nauck, M.A., Kranz, D., Holst, J.J., Deacon, C.F., Gaeckler, D., Schmidt, W.E., and Gallwitz,
   B. (2004). Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric
   inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.
   Diabetes 53, 654-662. 10.2337/diabetes.53.3.654.
- 490 37. Daniels, D., and Mietlicki-Baase, E.G. (2019). Glucagon-Like Peptide 1 in the Brain: Where Is It 491 Coming From, Where Is It Going? Diabetes *68*, 15-17. 10.2337/dbi18-0045.
- 38. Scrocchi, L.A., Brown, T.J., MaClusky, N., Brubaker, P.L., Auerbach, A.B., Joyner, A.L., and Drucker,
  D.J. (1996). Glucose intolerance but normal satiety in mice with a null mutation in the glucagonlike peptide 1 receptor gene. Nat Med 2, 1254-1258. 10.1038/nm1196-1254.
- 39. Song, Y., Koehler, J.A., Baggio, L.L., Powers, A.C., Sandoval, D.A., and Drucker, D.J. (2019). Gut Proglucagon-Derived Peptides Are Essential for Regulating Glucose Homeostasis in Mice. Cell
   Metab 30, 976-986 e973. 10.1016/j.cmet.2019.08.009.
- 498 40. Lampropoulos, C., Alexandrides, T., Tsochatzis, S., Kehagias, D., and Kehagias, I. (2021). Are the
   499 Changes in Gastrointestinal Hormone Secretion Necessary for the Success of Bariatric Surgery? A
   500 Critical Review of the Literature. Obes Surg *31*, 4575-4584. 10.1007/s11695-021-05568-7.
- 41. Papamargaritis, D., and le Roux, C.W. (2021). Do Gut Hormones Contribute to Weight Loss and Glycaemic Outcomes after Bariatric Surgery? Nutrients *13*. 10.3390/nu13030762.
- 42. Yousseif, A., Emmanuel, J., Karra, E., Millet, Q., Elkalaawy, M., Jenkinson, A.D., Hashemi, M., Adamo,
   M., Finer, N., Fiennes, A.G., et al. (2014). Differential effects of laparoscopic sleeve gastrectomy
   and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active
   GLP-1 levels in non-diabetic humans. Obes Surg 24, 241-252. 10.1007/s11695-013-1066-0.
- 43. Flint, A., Raben, A., Ersboll, A.K., Holst, J.J., and Astrup, A. (2001). The effect of physiological levels of
   glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in
   obesity. International journal of obesity and related metabolic disorders : journal of the
   International Association for the Study of Obesity 25, 781-792. 10.1038/sj.ijo.0801627.

- 44. Flint, A., Raben, A., Astrup, A., and Holst, J.J. (1998). Glucagon-like peptide 1 promotes satiety and
   suppresses energy intake in humans. The Journal of clinical investigation *101*, 515-520.
   10.1172/JCl990.
- 45. Long, S.J., Sutton, J.A., Amaee, W.B., Giouvanoudi, A., Spyrou, N.M., Rogers, P.J., and Morgan, L.M.
  (1999). No effect of glucagon-like peptide-1 on short-term satiety and energy intake in man. The
  British journal of nutrition *81*, 273-279.
- 46. Smits, M.M., and Holst, J.J. (2023). Endogenous glucagon-like peptide (GLP)-1 as alternative for GLP-1 receptor agonists: Could this work and how? Diabetes Metab Res Rev, e3699.
- 519 10.1002/dmrr.3699.